Company / Accounts Receivable
Insulet Corporation Accounts Receivable History
FY2016-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$140.9M
FY2022
5-year range
$135.2M / $140.9M
FY2018-FY2022
Trend
+4.2%
vs FY2021
Sector context
#86 of 143
Health Care
What the data says
At $141M, Insulet Corporation's accounts receivable ranks #86 of 143 in the Health Care sector. Accounts Receivable has increased for 6 consecutive years, from $29M in FY2016 to $141M in FY2022.
Based on SEC 10-K filings.
$141M in FY2022 with a 5-year CAGR of +21.4%.
Improved from $95M to $141M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +26.7%
- 5-Year CAGR
- +21.4%
- 10-Year CAGR
- -
Sector benchmark
#86 of 143 in Health CareTop 60% of 143This company $140.9M Sector average $1.3B
▼
-89.4% below sector average
Key checks
Key Insights
- Insulet Corporation's accounts receivable has grown for 6 consecutive years.
- 5-year CAGR of +21.4%, indicating consistent growth.
- In FY2022, accounts receivable increased 4.2% year-over-year.
- Ranks #86 out of 143 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 20.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $140.9M | +4.2% |
| FY2021 | $135.2M | +41.9% |
| FY2020 | $95.3M | +37.5% |
| FY2019 | $69.3M | +9.5% |
| FY2018 | $63.3M | +18.6% |
| FY2017 | $53.4M | +85.3% |
| FY2016 | $28.8M | -32.3% |
As of FY2022 · SEC 10-K · Updated Feb 28, 2026